Trifecta-Heart cfDNA-MMDx Study

Description

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

Conditions

Heart Transplant Rejection

Talk to us

Study Overview

On this page

Study Details

Study overview

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

Trifecta-Heart cfDNA-MMDX Study: Comparing the DD-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test

Trifecta-Heart cfDNA-MMDx Study

Condition
Heart Transplant Rejection
Intervention / Treatment

-

Contacts and Locations

Little Rock

Baptist Health Institute for Research and Innovation, Little Rock, Arkansas, United States, 72205

W. New York

Columbia University Medical Center, Columbia Interventional Cardiovascular Care, W. New York, New Jersey, United States, 10032

Bronx

Montefiore Medical Center, 3319 Rochambeau Avenue, 2nd FL, Bronx, New York, United States, 10467

Dallas

Annette C. and Harold C. Simmons Transplant Institute, BaylorScott&White Research Institute, Dallas, Texas, United States, 75246

Salt Lake City

Cardiovascular Medicine, University of Utah Health, Salt Lake City, Utah, United States, 84132

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All heart transplant recipients undergoing a biopsy for clinical indications and protocol biopsies, as determined by their physician or surgeon, will be eligible to enroll in the study.
  • * Patients are enrolled based on standard of care biopsies, including surveillance biopsies in high-risk patients, with informed consent.
  • * Patients will be excluded from the study if they decline participation
  • * Are unable to give informed consent.
  • * Recipients of multiple organs.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alberta,

Philip F Halloran, MD PhD, PRINCIPAL_INVESTIGATOR, Alberta Transplant Applied Genomics Center, University of Alberta

Study Record Dates

2027-07